


LIST OF TABLES

	Page
Table I	11
Table II	11
Table 1.1	21
Table 1.2	21
Table 1.3	22
Table 1.4	22
Table 1.5	23
Table 1.6	23
Table 1.7	24
Table 1.8	24
Table 1.9	25
Table 1.10	26
Table 1.11	27
Table 1.12	28
Table 1.13	29
Table 2.1	34
Table 2.2	35
Table 2.3	35
Table 2.4	36
Table 2.5	37
Table 2.6	37
Table 2.7	38
Table 2.8	39
Table 2.9	39
Table 2.10	40
Table 2.11	41
Table 2.12	44
Table 2.13	44
Table 2.14	45



	Page	
Table 2.15	Biological subtypes of invasive tumours by cancer stage (N=15,688)	46
Table 2.16	Histological type, grading, multifocality and multicentricity of in situ breast cancer (N=2,514)	47
Table 2.17	Biological characteristics of in situ breast cancer (N=2,514)	47
Table 2.18	Number of treatment modalities by cancer stage (N=19,150)	48
Table 2.19	Use of surgery for patients with invasive or in situ cancer	49
Table 2.20	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=7,416)	53
Table 2.21	Use of chemotherapy by age group and cancer stage at diagnosis (N=16,235)	54
Table 2.22	Follow-up of patients (N=18,014)	63
Table 2.23	Recurrence pattern of patients (N=17,402)	63
Table 2.24	Locoregional recurrence by type of surgery received and cancer stage at diagnosis	64
Table 2.25	Sites involved in locoregional recurrence (N=781)	64
Table 2.26	Sites involved in distant recurrence (N=905)	65
Table 2.27	Time for organ specific metastasis and distribution of the biological subtypes of patients	65
Table 2.28	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage (N=14,745)	66
Table 2.29	Characteristics of breast cancer-specific deaths (N=990)	66
Table 3.1	Psychosocial impact of breast cancer	72
Table 3.2	Psychosocial adjustments and coping strategies for survivorship	73
Table 4.1	Ten most common risk factors for breast cancer in patient cohort (N=1,682)	77
Table 4.2	Breast screening habits	78
Table 4.3	Biological subtypes of invasive tumours by cancer stage (N=759)	80
Table 4.4	Number of treatment modalities by cancer stage (N=985)	81

LIST OF FIGURES

	Page
Figure I	7
Figure 1.1	17
Figure 1.2	17
Figure 1.3	18
Figure 1.4	18
Figure 1.5	18
Figure 1.6	19
Figure 1.7	19
Figure 1.8	20
Figure 1.9	20
Figure 1.10	20
Figure 1.11	21
Figure 1.12	25
Figure 2.1	34
Figure 2.2	35
Figure 2.3	36
Figure 2.4	38
Figure 2.5	39
Figure 2.6	41
Figure 2.7	42
Figure 2.8	42
Figure 2.9	43
Figure 2.10	43
Figure 2.11	50
Figure 2.12	50
Figure 2.13	50
Figure 2.14	50
Figure 2.15	51
Figure 2.16	51
Figure 2.17	51
Figure 2.18	52
Figure 2.19	53
Figure 2.20	53
Figure 2.21	54



Figure 2.22	Type of first generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=161)	55
Figure 2.23	Type of second generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=137)	55
Figure 2.24	Type of third generation chemotherapy regimens (non-HER2) used in neoadjuvant setting (N=525)	55
Figure 2.25	Type of HER2 regimens used in neoadjuvant setting (N=434)	55
Figure 2.26	Type of chemotherapy regimens used by biological subtype in neoadjuvant setting (N=1,226)	56
Figure 2.27	Type of first generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=1,671)	57
Figure 2.28	Type of second generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,694)	57
Figure 2.29	Type of third generation chemotherapy regimens (non-HER2) used in adjuvant setting (N=2,761)	57
Figure 2.30	Type of HER2 regimens used in adjuvant setting (N=875)	57
Figure 2.31	Type of chemotherapy regimens used by biological subtype in adjuvant setting (N=8,321)	58
Figure 2.32	Type of chemotherapy regimens used by cancer stage in adjuvant setting (N=8,457)	59
Figure 2.33	Type of chemotherapy regimens used by biological subtype in palliative setting (N=240)	60
Figure 2.34	Use of endocrine therapy by cancer stage (N=19,086)	61
Figure 2.35	Forms of endocrine therapy by age group (N=12,289)	61
Figure 2.36	Type of targeted therapy drugs used (N=2,864)	62
Figure 2.37	Use of anti-HER2 targeted therapy in HER2 positive patients by cancer stage (N=3,477)	62
Figure 2.38	Type of complementary and alternative therapies used (N=7,155)	63
Figure 3.1	Level of physical discomfort after surgery (N=17,696)	69
Figure 3.2	Level of physical discomfort by type of surgery (N=17,645)	69
Figure 3.3	Level of physical discomfort after radiotherapy (N=10,169)	69
Figure 3.4	Level of physical discomfort after radiotherapy by irradiated regions (N=6,775)	70
Figure 3.5	Level of physical discomfort after chemotherapy (N=10,367)	70
Figure 3.6	Level of physical discomfort after endocrine therapy (N=11,234)	70
Figure 3.7	Level of physical discomfort after targeted therapy (N=2,306)	71
Figure 3.8	Level of physical discomfort after complementary and alternative therapies (N=6,930)	71
Figure 3.9	Change in outlook on life by age group (N=17,150)	72
Figure 3.10	Change in self-image by age group (N=17,147)	73
Figure 3.11	Level of worry about recurrence by age group (N=17,151)	73
Figure 4.1	Distribution of age at diagnosis (N=1,682)	77
Figure 4.2	Education level of patient cohort (N=1,682)	77
Figure 4.3	Distribution of risk factors among patients at diagnosis (N=1,682)	77
Figure 4.4	Methods of first breast cancer detection in the patient cohort (N=1,032)	78
Figure 4.5	Time interval between onset of symptoms and first medical consultation for patients who self-detected their cancer (N=388)	78
Figure 4.6	Cancer stage at diagnosis (N=1,052)	79
Figure 4.7	Distribution of tumour size (cm) of invasive breast cancer (N=666)	79
Figure 4.8	Number of positive axillary lymph nodes among patients with invasive breast cancer (N=683)	79
Figure 4.9	Distribution of tumour size (cm) of in situ breast cancer (N=177)	80